Abstract
The skin locally synthesizes significant amounts of sexual hormones with intracrine or paracrine actions. The local level of each sexual steroid depends upon the expression of each of the androgen- and estrogen-synthesizing enzymes in each cell type, with sebaceous glands and sweat glands being the major contributors. Sebocytes express very little of the key enzyme, cytochrome P450c17, necessary for synthesis of the androgenic prohormones dehydroepiandrosterone and androstenedione, however, these prohormones can be converted by sebocytes and sweat glands, and probably also by dermal papilla cells, into more potent androgens like testosterone and dihydrotestosterone. Five major enzymes are involved in the activation and deactivation of androgens in skin. Androgens affect several functions of human skin, such as sebaceous gland growth and differentiation, hair growth, epidermal barrier homeostasis and wound healing. Their effects are mediated by binding to the nuclear androgen receptor. Changes of isoenzyme and/or androgen receptor levels may have important implications in the development of hyperandrogenism and the associated skin diseases such as acne, seborrhoea, hirsutism and androgenetic alopecia. On the other hand, estrogens have been implicated in skin aging, pigmentation, hair growth, sebum production and skin cancer. Estrogens exert their actions through intracellular receptors or via cell surface receptors, which activate specific second messenger signaling pathways. Recent studies suggest specific site-related distribution of ERα and ERβ in human skin. In contrast, progestins play no role in the pathogenesis of skin disorders. However, they play a major role in the treatment of hirsutism and acne vulgaris, where they are prescribed as components of estrogen-progestin combination pills and as anti-androgens. These combinations enhance gonadotropin suppression of ovarian androgen production. Estrogen-progestin treatment can reduce the need for shaving by half and arrest progression of hirsutism of various etiologies, but do not necessarily reverse it. However, they reliably reduce acne. Cyproterone acetate and spironolactone are similarly effective as anti-androgens in reducing hirsutism, although there is wide variability in individual responses.
Key words
androgens - estrogens - progestins - human skin - acne
References
1
Imperato-McGinley J, Gautier T, Cai L-Q, Yee B, Epstein J, Pochi P.
The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
J Clin Endocrinol Metab.
1993;
76
524-528
2
Zouboulis CC.
Human skin: an independent peripheral endocrine organ.
Horm Res.
2000;
54
230-242
3
Rosenfield RL.
Hirsutism and the variable response of the pilosebaceous unit to androgen.
J Investig Dermatol Symp Proc.
2005;
10
205-208
4
Rosenfield RL.
Role of androgens in growth and development of the fetus, child, and adolescent.
Adv Pediatr.
1972;
19
171-213
5
Stewart ME, Downing DT, Cook JS, Hansen JR, Strauss JS.
Sebaceous gland activity and serum dehydroepiandrosteron sulfate levels in boys and girls.
Arch Dermatol.
1992;
128
1345-1348
6
Marynick SP, Chakmakjian ZH, McCaffree DL, Herndon JH.
Androgen excess in cystic acne.
N Engl J Med.
1983;
308
981-986
7
Pochi PE, Strauss JS.
Sebaceous gland response in man to the administration of testosterone, Δ4-androstenedione, and dehydroisoandrosterone.
J Invest Dermatol.
1969;
52
32-36
8
Messenger AG.
The control of hair growth: an overview.
J Invest Dermatol.
1993;
101
4S-9S
9
Deplewski D, Rosenfield RL.
Role of hormones in pilosebaceous unit development.
Endocrine Rev.
2000;
21
363-392
10
Verrijdt G, Haelens A, Claessens F.
Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression.
Mol Genet Metab.
2003;
78
175-185
11
Zouboulis CC.
The human skin as a hormone target and an endocrine gland.
Hormones.
2004;
3
9-26
12
Zouboulis CC, Degitz K.
Androgen action on human skin - From basic research to clinical significance.
Exp Dermatol.
2004;
13
((Suppl 4))
5-10
13
Gad YZ, Berkovitz GD, Migeon CJ, Brown TR.
Studies of up-regulation of androgen receptors in genital skin fibroblasts.
Mol Cell Endocrinol.
1988;
57
205-213
14
Fimmel S, Saborowski A, Térouanne B, Sultan C, Zouboulis CC.
Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes.
Horm Metab Res.
, in press
15
Ibanez L, Ong KK, Mongan N, Jaaskelainen J, Marcos MV, Hughes IA, De Zegher F, Dunger DB.
Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism.
J Clin Endocrinol Metab.
2003;
88
3333-3338
16
Hillmer AM, Hanneken S, Ritzmann S, Becker T, Freudenberg J, Brockschmidt FF, Flaquer A, Freudenberg-Hua Y, Jamra RA, Metzen C, Heyn U, Schweiger N, Betz RC, Blaumeiser B, Hampe J, Schreiber S, Schulze TG, Hennies HC, Schumacher J, Propping P, Ruzicka T, Cichon S, Wienker TF, Kruse R, Nothen MM.
Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.
Am J Hum Genet.
2005;
77
140-148
17
Fritsch M, Orfanos CE, Zouboulis CC.
Sebocytes are the key regulators of androgen homeostasis in human skin.
J Invest Dermatol.
2001;
116
793-800
18
Thiboutot D, Martin P, Volikos L, Gilliland K.
Oxidative activity of the type 2 isozyme of 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) predominates in human sebaceous glands.
J Invest Dermatol.
1998;
111
390-395
19
Chen W, Thiboutot D, Zouboulis CC.
Cutaneous androgen metabolism - Basic research and clinical perspectives.
J Invest Dermatol.
2002;
119
992-1007
20
Milewich L, Sontheimer RD, Herndon Jr JH.
Steroid sulfatase activity in epidermis of acne-prone and non-acne-prone skin of patients with acne vulgaris.
Arch Dermatol.
1990;
126
1312-1314
21
Billich A, Rot A, Lam C, Schmidt JB, Schuster I.
Immunohistochemical localization of steroid sulfatase in acne lesions: implications for the contribution of dehydroepiandrosterone sulfate to the pathogenesis of acne (abstract).
Hormone Res.
2000;
53
99
22
Hoffmann R, Rot A, Niiyama S, Billich A.
Steroid sulfatase in the human hair follicle concentrations in the dermal papilla.
J Invest Dermatol.
2001;
117
1342-1348
23
Sakurai N, Miki Y, Suzuki T, Watanabe K, Narita T, Ando K, Yung TM, Aoki D, Sasano H, Handa H.
Systemic distribution and tissue localizations of human 17beta-hydroxysteroid dehydrogenase type 12.
J Steroid Biochem Mol Biol.
2006;
99
174-181
24
Hoppe U, Holterhus PM, Wunsch L, Jocham D, Drechsler T, Thiele S, Marschke C, Hiort O.
Tissue-specific transcription profiles of sex steroid biosynthesis enzymes and the androgen receptor.
J Mol Med.
2006;
84
651-659
25
Courchay G, Boyera N, Bernard BA, Mahe Y.
Messenger RNA expression of steroidogenesis enzyme subtypes in the human pilosebaceous unit.
Skin Pharmacol.
1996;
9
169-176
26
Grino PB, Griffin JE, Wilson JD.
Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone.
Endocrinology.
1990;
126
1165-1172
27
Chen W, Zouboulis CC, Fritsch M, Blume-Peytavi U, Kodelja V, Goerdt S, Luu-The V, Orfanos CE.
Evidence of heterogeneity and quantitative differences of the type1 5α-reductase expression in cultured human skin cells - First evidence of its presence in melanocytes.
J Invest Dermatol.
1998;
110
84-89
28
Qin K, New MI, Cheng KC.
Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase.
J Steroid Biochem Mol Biol.
1993;
46
673-679
29
Thornton MJ, Nelson LD, Taylor AH, Birch MP, Laing I, Messenger AG.
The modulation of aromatase and estrogen receptor alpha in cultured human dermal papilla cells by dexamethasone: a novel mechanism for selective action of estrogen via estrogen receptor beta?.
J Invest Dermatol.
2006;
126
2010-2018
30
Chen W, Yang CC, Liao CY, Hung CL, Tsai SJ, Chen KF, Sheu HM, Zouboulis CC.
Expression of sex-determining genes in human sebaceous glands and their possible roles in pathogenesis of acne.
J Eur Acad Dermatol Venereol.
2006;
20
846-852
31
Patel MV, McKay IA, Burrin JM.
Transcriptional regulators of steroidogenesis, DAX-1 and SF-1, are expressed in human skin.
J Invest Dermatol.
2001;
117
1559-1565
32
Thiboutot D, Chen W.
Update and future of hormonal therapy in acne.
Dermatology.
2003;
206
57-67
33
Lookingbill DP, Horton R, Demers LM, Egan N, Marks Jr JG, Santen RJ.
Tissue production of androgens in women with acne.
J Am Acad Dermatol.
1985;
12
481-487
34
Akamatsu H, Zouboulis CC, Orfanos CE.
Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands.
J Invest Dermatol.
1992;
99
509-511
35
Chen W, Yang C-C, Sheu H-M, Seltmann H, Zouboulis CC.
Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes.
J Invest Dermatol.
2003;
121
441-447
36
Makrantonaki E, Zouboulis CC.
Testosterone metabolism to 5α-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferators-activated receptor ligand linoleic acid in human sebocytes.
Brit J Dermatol.
, in press
37
Asada Y, Sonoda T, Ojiro M, Kurata S, Sato T, Ezaki T, Takayasu S.
5alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro.
J Clin Endocrinol Metab.
2001;
86
2875-2880
38
Sawaya ME, Shalita AR.
Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne.
J Cutan Med Surg.
1998;
3
9-15
39
Paus R.
The biology of hair follicles.
N Engl J Med.
1999;
341
491-497
40
Ando Y, Yamaguchi Y, Hamada K, Yoshikawa K, Itami S.
Expression of mRNA for androgen receptor, 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase in human dermal papilla cells.
Brit J Dermatol.
1999;
141
840-845
41
Winiarska A, Mandt N, Kamp H, Hossini A, Seltmann H, Zouboulis CC, Blume-Peytavi U.
Effect of 5alpha-dihydrotestosterone and testosterone on apoptosis in human dermal papilla cells.
Skin Pharmacol Physiol.
2006;
19
311-321
42
Serafini P, Ablan F, Lobo RA.
5alpha-Reductase activity in the genital skin of hirsute women.
J Clin Endocrinol Metab.
1985;
60
349-355
43
Randall VA, Thornton MJ, Hamada K, Messenger AG.
Mechanism of androgen action in cultured dermal papilla cells derived from human hair follicles with varying responses to androgens in vivo.
J Invest Dermatol.
1992;
98
86S-91S
44
Kaufman KD, Dawber RP.
Finasteride, a type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia.
Expert Opin Investig Drugs.
1999;
8
403-415
45
Chen W, Tsai S-J, Liao C-Y, Tsai R-Y, Chen Y-R, Pan B-J, Hung C-L, Zouboulis CC.
Higher levels of steroidogenic acute regulatory protein and type I 3β-hydroxysteroid dehydrogenase in the scalp of men with androgenetic alopecia.
J Invest Dermatol.
2006;
126
2332-2335
46
Kim SS, Rosenfield RL.
Hyperhydrosis as the only manifestation of hyperandrogenism in an adolescent girl.
Arch Dermatol.
2000;
136
430-431
47
Kurata S, Itami S, Komada S, Takayasu S.
Intranuclear androgen and cytosolic receptor concentrations in the axillary skin of osmidrosis.
Arch Dermatol Res.
1990;
282
33-37
48
Sato T, Sonoda T, Itami S, Takayasu S.
Predominance of type I 5alpha-reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis).
Br J Dermatol.
1998;
139
806-810
49
Kao JS, Garg A, Mao-Qiang M.
Testosterone perturbs epidermal permeability barrier homeostasis.
J Invest Dermatol.
2001;
116
443-451
50
Ashcroft G, Mills S.
Androgen receptor-mediated inhibition of cutaneous wound healing.
J Clin Invest.
2002;
110
615-624
51
Gilliver SC, Ashworth JJ, Mills SJ, Hardman MJ, Ashcroft GS.
Androgens modulate the inflammatory response during acute wound healing.
J Cell Sci.
2006;
119
722-732
52
Fimmel S, Zouboulis CC.
Influence of physiological androgen levels on wound healing and immune status in men.
Aging Male.
2005;
8
166-174
53
Lucky AW.
A review of infantile and pediatric acne.
Dermatology.
1998;
196
95-97
54
New MI.
An update of congenital adrenal hyperplasia.
Ann N Y Acad Sci.
2004;
1038
14-43
55
Imperato-McGinley J.
5alpha-reductase-2 deficiency and complete androgen insensitivity: lessons from nature.
Adv Exp Med Biol.
2002;
511
121-131
56
Eklof AC, Thurelius AM, Garle M, Rane A, Sjoqvist F.
The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology.
Eur J Clin Pharmacol.
2003;
59
571-577
57
Cappel M, Mauger D, Thiboutot D.
Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women.
Arch Dermatol.
2005;
141
333-338
58
Guy R, Ridden C, Kealey T.
The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red.
J Invest Dermatol.
1996;
106
454-460
59
Deplewski D, Liao S, Rosenfield RL.
Preputial sebocyte 5alpha-reductase isoform specificity.
Endocrinology.
1997;
138
4416-4420
60
Rosenfield RL, Deplewski D, Kentsis A, Ciletti N.
Mechanisms of androgen induction of sebocyte differentiation.
Dermatology.
1998;
196
43-46
61
Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE.
Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95).
J Invest Dermatol.
1999;
113
1011-1020
62
Zouboulis CC, Piquero-Martin J.
Update and future of systemic acne treatment.
Dermatology.
2003;
206
37-53
63
van Vloten WA, Sigurdsson V.
Selecting an oral contraceptive agent for the treatment of acne in women.
Am J Clin Dermatol.
2004;
5
435-441
64
Thiboutot DM, Knaggs H, Gilliland K, Hagari S.
Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis.
Brit J Dermatol.
1997;
136
166-171
65
Carmina E, Godwin AJ, Stanczyk FZ, Lippman JS, Lobo RA.
The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.
J Endocrinol Invest.
2002;
25
765-768
66
Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM, Bornstein SR.
Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes.
Proc Nat Acad Sci USA.
2002;
99
7148-7153
67
Baillie AH, Thomson J, Milne JA.
The distribution of hydroxysteroid dehydrogenase in human sebaceous glands.
Br J Dermatol.
1966;
78
451-457
68
Billich A, Meingassner JG, Nussbaumer P, Desrayaud S, Lam C, Winiski A, Schreiner E.
6-[2-(adamantylidene)-hydroxybenzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases.
J Steroid Biochem Mol Biol.
2004;
92
29-37
69
Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S.
Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin.
J Invest Dermatol.
1995;
105
209-214
70
Thiboutot D, Gilliland K, Light J, Lookingbill D.
Androgen metabolism in sebaceous glands from subjects with and without acne.
Arch Dermatol.
1999;
135
1041-1045
71
Leyden J, Bergfeld W, Drake L, Dunlap F, Goldman MP, Gottlieb AB, Heffernan MP, Hickman JG, Hordinsky M, Jarrett M, Kang S, Lucky A, Peck G, Phillips T, Rapaport M, Roberts J, Savin R, Sawaya ME, Shalita A, Shavin J, Shaw JC, Stein L, Stewart D, Strauss J, Swinehart J, Swinyer L, Thiboutot D, Washenik K, Weinstein G, Whiting D, Pappas F, Sanchez M, Terranella L, Waldstreicher J.
A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris.
J Am Acad Dermatol.
2004;
50
443-447
72
Thiboutot D, Bayne E, Thorne J, Gilliland K, Flanagan J, Shao Q, Light J, Helm K.
Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin.
Arch Dermaol.
2000;
136
1125-1129
73
Mindnich R, Moller G, Adamski J.
The role of 17 beta-hydroxysteroid dehydrogenases.
Mol Cell Endocrinol.
2004;
218
7-20
74
Orfanos CE, Adler YD, Zouboulis CC.
The SAHA syndrome.
Horm Res.
2000;
54
251-258
75
Adler YD, Orfanos CE, Zouboulis CC.
HAIRAN syndrome: a fifth variant of SAHA syndrome (abstract).
Horm Res.
2000;
53
94
76
Speiser PW, White PC.
Congenital adrenal hyperplasia.
New Engl J Med.
2003;
349
776-788
77
Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Fluck CE, Miller WL.
Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.
Am J Hum Genet.
2005;
76
729-749
78
Ramsay B, Alaghband Zadeh J, Carter G, Wheeler MJ, Cream JJ.
Raised serum 11-deoxycortisol in men with persistent acne vulgaris.
Clin Endocrinol Oxf.
1995;
43
305-310
79
Jabbour SA.
.
Am J Clin Dermatol.
2003;
4
315-331
80
Zouboulis CC.
Therapie der Akne mit Antiandrogenen - Eine evidenzbasierte Übersicht.
J Dtsch Dermatol Ges.
2003;
1
535-546
81
Sitruk-Ware R.
Pharmacology of different progestogens: the special case of drospirenone.
Climacteric.
2005;
8
((Suppl 3))
4-12
82
Degitz K, Placzek M, Arnold B, Schmidt H, Plewig G.
Congenital adrenal hyperplasia and acne in male patients.
Brit J Dermatol.
2003;
148
1263-1266
83
Zouboulis CC.
Moderne Aknetherapie.
Akt Dermatol.
2003;
29
49-57
84
Thornton MJ.
The biological actions of estrogens on skin.
Exp Dermatol.
2002;
11
487-502
85
Thornton MJ.
Oestrogen functions in skin and skin appendages.
Expert Opin Ther Targets.
2005;
9
617-629
86
Brincat MP.
Hormone replacement therapy and the skin.
Maturitas.
2000;
29
107-117
87
Sator PG, Schmidt JB, Rabe T, Zouboulis CC.
Skin aging and sex hormones in women - clinical perspectives for intervention by hormone replacement therapy.
Exp Dermatol.
2004;
13
((Suppl 4))
36-40
88
Shah MG, Maibach HI.
Estrogen and skin.
An overview Am J Clin Dermatol.
2001;
2
143-150
89
Brincat M, Versi E, Moniz CF, Magos A, De Trafford J, Studd JW.
Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy.
Obstet Gynecol.
1987;
70
123-127
90
Varila E, Rantala I, Oikarinen A, Risteli J, Reunala T, Oksanen H, Punnonen R.
The effect of topical estradiol on skin collagen of postmenopausal women.
Br J Obstet Gynaecol.
1995;
102
985-989
91
Sumino H, Ichikawa S, Abe M, Endo Y, Ishikawa O, Kurabayashi M.
Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women.
J Am Geriatr Soc.
2004;
52
945-949
92
Ashcroft Gs, Ashworth JJ.
Potential role of estrogens in wound healing.
Am J Clin Dermatol.
2003;
4
737-743
93
Boyd AS, Morris LF, Phillips CM, Menter MA.
Psoriasis and pregnancy: hormone and immune system interaction.
Int J Dermatol.
1996;
35
169-172
94
Raychaudhuri SP, Navare T, Gross J, Raychaudhuri SK.
Clinical course of psoriasis during pregnancy.
Int J Dermatol.
2003;
42
518-520
95
Dunna SF, Finlay AY.
Psoriasis: improvement during and worsening after pregnancy.
Br J Dermatol.
1989;
120
584
96
Weinstock MA.
Epidemiologic investigation of non melanoma skin cancer mortality: the Rhode Island Follow-Back Study.
J Invest Dermatol.
1994;
102
6S-9S
97
Miller JG, Mac Neil S.
Gender and cutaneous melanoma.
Br J Dermatol.
1997;
136
657-665
98
Hasselquist MB, Goldberg N, Schroeter A, Spelsberg TC.
Isolation and characterisation of the estrogen receptor in human skin.
J Clin Endocrinol Metab.
1980;
50
76-82
99
Punnonen R, Lovgrent T, Kouvonen I.
Demonstration of estrogen receptors in the skin.
J Endocrinol Invest.
1980;
3
217-221
100
Gustafsson JA.
An update on estrogen receptors.
Semin Perinatol.
2000;
24
66-69
101
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA.
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β.
Endocrinol.
1997;
138
863-870
102
Levin ER.
Cellular functions of plasma membrane estrogen receptors.
Steroids.
2002;
67
471-475
103
Nadal A, Ropero AB, Fuentes E, Soria B.
The plasma membrane estrogen receptor: nuclear or unclear?.
Trends Pharm Sci.
2001;
22
597-599
104
Aronica SM, Kraus WL, Katzenellenbogen BS.
Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription.
Proc Natl Acad Sci USA.
1994;
91
8517-8521
105
Shaul PW.
Rapid activation of endothelial nitric oxide synthase by estrogen.
Steroids.
1999;
64
28-34
106
Pappas TC, Gametchu B, Watson CS.
Membrane estrogen receptors identified by multiple antibody labelling and impeded-ligand binding.
FASEB J.
1995;
9
404-410
107
Razandi M, Pedram A, Greene GL, Levin ER.
Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells.
Mol Endocrinol.
1999;
13
307-319
108
Benten WPM, Stephan C, Lieberherr M, Wunderlich F.
Estradiol signalling via sequestrable surface receptors.
Endocrinol.
2001;
142
1669-1677
109
Saji S, Hirose M, Toi M.
Clinical significance of estrogen receptor beta in breast cancer.
Cancer Chemother Pharmacol.
2005;
56
((Suppl 1))
21-26
110
Mosselman S, Polman J, Dijkema R.
ERβ. Identification and characterisation of a novel human estrogen receptor.
FEBS Lett.
1996;
392
49-53
111
Thornton MJ, Taylor AH, Mulligan K, Al-Azzawi F, Lyon CC, O’Driscoll JB, Messenger AG.
Estrogen receptor beta (ERβ) is the predominant estrogen receptor in human scalp.
Exp Dermatol.
2003;
12
181-190
112
Thornton MJ, Taylor AH, Mulligan K, Al-Azzawi F, Lyon CC, O’Driscoll JB, Messenger AG.
The distribution of estrogen receptor beta (ERβ) is distinct to that of ER alpha and the androgen receptor in human skin and the pilosebaceous unit.
J Investig Dermatol Symp Proc.
2003;
8
100-103
113
Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB.
Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus.
J Clin Endocrinol Metab.
1997;
82
3509-3512
114
Kanda N, Watanabe S.
17beta-estradiol inhibits the production of interferon-induced protein of 10 kDa by human keratinocytes.
J Invest Dermatol.
2003;
120
411-419
115
Kanda N, Watanabe S.
17beta-estradiol inhibits the production of RANTES in human keratinocytes.
J Invest Dermatol.
2003;
120
420-427
116
Verdier-Sevrain S, Yaar M, Cantatore J, Traish A, Gilchrest BA.
Estradiol induces proliferation of keratinocytes via a receptor mediated mechanism.
FASEB J.
2004;
18
1252-1254
117
Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS.
Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture.
Proc Natl Acad Sci USA.
1986;
83
2496-2500
118
Kanda N, Watanabe S.
17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression.
J Invest Dermatol.
2004;
123
319-328
119
Haczynski J, Tarkowski R, Jarzabek K, Slomczynska M, Wolczynski S, Magoffin DA, Jakowicki J, Jakimiuk AJ.
Human cultured skin fibroblasts express estrogen receptor alpha and beta.
Int J Mol Med.
2002;
10
149-153
120
Haczynski J, Tarkowski R, Jarzabek K, Wolczynski S, Magoffin DA, Czarnocki KJ, Ziegert M, Jakowicki J, Jakimiuk AJ.
Differential effects of estradiol, raloxifene and tamoxifen on estrogen receptor expression in cultured human skin fibroblasts.
Int J Mol Med.
2004;
13
903-908
121
Conrad F, Paus R.
strogene und der Haarfollikel.
J Dtsch Dermatol Ges.
2004;
2
412-423
122
Chanda S, Robinette CL, Couse JF, Smart RC.
17beta-estradiol and ICI-182780 regulate the hair follicle cycle in mice through an estrogen receptor-alpha pathway.
Am J Physiol Endocrinol Metab.
2000;
278
E202-E210
123
Ohnemus U, Uenalan M, Conrad F, Handjiski B, Mecklenburg L, Nakamura M, Inzunza J, Gustafsson JA, Paus R.
Hair cycle control by estrogens: Catagen induction via ER(alpha) is checked by ER(beta) signalling.
Endocrinology.
2005;
145
1214-1225
124
Conrad F, Ohnemus U, Bodo E, Biro T, Tychsen B, Gerstmayer B, Bosio A, Schmidt-Rose T, Altgilbers S, Bettermann A, Saathoff M, Meyer W, Paus R.
Substantial sex-dependent differences in the response of human scalp hair follicles to estrogen stimulation in vitro advocate gender-tailored management of female versus male pattern ba ding.
J Invest Dermatol Symp Proc.
2005;
10
243-246
125
Sansone-Bazzano G, Reisner RM, Bazzano G.
A possible mechanism of action of estrogen at the cellular level in a model sebaceous gland.
J Invest Dermatol.
1972;
59
299-304
126
Mesquita-Guimaraes J, Coimbra A.
The effect of sexual hormones on the lipid and proteinaceous secretion of the rat preputial sebaceous gland.
Arch Dermatol Res.
1981;
270
325-331
127 Plewig G, Kligman AM. Acne and Rosacea 3rd ed. Berlin: Springer 2003
128
Kariya Y, Moriya T, Suzuki T, Chiba M, Ishida K, Takeyama J, Endoh M, Watanabe M, Sasano H.
Sex steroid hormone receptors in human skin appendage and its neoplasms.
Endocr J.
2005;
52
317-325
129
Beier K, Ginez I, Schaller H.
Localization of steroid hormone receptors in the apocrine sweat glands of the human axilla.
Histochem Cell Biol.
2005;
123
61-65
130
Simpson ER, Zhao Y, Agarwal VR.
, et al
Aromatase expression in health and disease.
Recent Prog Horm Res.
1997;
52
185-213
131
Simpson ER.
Role of aromatase in sex steroid action.
J Mol Endocrinol.
2000;
25
149-156
132
Harada N.
A new aspect of the pharmacological and physiological significance of the aromatase/estrogen system.
(in Japanese) Nippon Yakurigaku Zasshi - Folia Pharmacologica Japonica.
1998;
112
51-58
133
Harada N.
Aromatase and intracrinology of estrogen in hormone-dependent tumors.
Oncology.
1999;
57
((Suppl 2))
7-16
134
Sawaya ME, Price VH.
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
J Invest Dermatol.
1997;
109
296-300
135
Hoffmann R, Niiyama S, Huth A, Kissling S, Happle R.
17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo.
Exp Dermatol.
2002;
11
376-380
136
Hughes SV, Robinson E, Bland R, Lewis HM, Stewart PM, Hewison M.
1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes.
Endocrinology.
1997;
138
3711-3718
137
Svenstrup B, Brunner N, Dombernowsky P, Nohr I, Micic S, Bennett P, Spang-Thomsen M.
Comparison of the effect of cortisol on aromatase activity and androgen metabolism in two human fibroblast cell lines derived from the same individual.
J Steroid Biochem.
1990;
35
679-687
138
Rink JD, Simpson ER, Barnard JJ, Bulun SE.
Cellular characterization of adipose tissue from various body sites of women.
J Clin Endocrinol Metab.
1996;
81
2443-2447
139
Kroumpouzos G, Cohen LM.
Dermatoses of pregnancy.
J Am Acad Dermatol.
2001;
45
1-19
140
Wade TR, Wade SL, Jones HE.
Skin changes and diseases associated with pregnancy.
Obstet Gynecol.
1978;
52
233-242
141
Beas F, Vargas L, Spada RP, Merchak N.
Pseudoprecocious puberty in infants caused by a dermal ointment containing estrogens.
J Pediatr.
1969;
75
127-130
142
Taylor AH, Thornton MJ, Messenger AG, Tobin DJ.
Human epidermal melanocytes express the androgen receptor and both estrogen receptors (ERα) and (ERβ) in situ.
J Invest Dermatol.
2002;
119
801
143
Jee SH, Lee SY, Chiu HC, Chang CC, Chen TY.
Effects of estrogen and estrogen receptor in normal human melanocytes.
Biochem Biophys Res Commun.
1994;
199
1407-1412
144
Im S, Lee ES, Kim W, On W, Kim J, Lee M, Kang WH.
Donor specific response of estrogen and progesterone on cultured human melanocytes.
J Korean Med Sci.
2002;
17
58-64
145 Meskiri AN, Thornton MJ, Tobin DJ. Expression of estrogen receptors in cutaneous melanocytes and their potential role in the regulation of pigment cell phenotype. In: Trüeb RM (ed) Understanding Hair Biology . European Hair Research Society, 11th Meeting, Zurich, Dermatology 2005; 211(special issue 1)
146
Meskiri AN, Thornton MJ, Tobin DJ.
, Induction of pigmentation up regulates ERalpha and aromatase in epidermal melanocytes and melanoma cells
http://http:/www.endocrine-abstracts.org
, 196th Meeting of the Society for Endocrinology, London, UK 7-9 November 2005, Endocrine Abstracts
2005;
10
78
147
Schleicher RL, Hitselberger MH, Beattie CW.
Inhibition of hamster melanoma growth by estrogen.
Cancer Res.
1987;
47
453-459
148
Hitselberger MH, Schleicher RL, Beattie CW.
Effects of estradiol on estrogen receptor, progesterone receptor, and tyrosinase in hamster melanoma transplanted into athymic mice.
Cancer Res.
1988;
48
3720-3727
149
Feucht KA, Walker MJ, Das Gupta TK, Beattie CW.
Effect of 17 beta-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice.
Cancer Res.
1988;
48
7093-7101
150
Armstrong LE, Maresh CM, Keith NR, Elliott TA, Vanheest JL, Scheett TP, Stoppani J, Judelson DA, De Souza MJ.
Heat acclimation and physical training adaptations of young women using different contraceptive hormones.
Am J Physiol Endocrinol Metab.
2005;
288
E868-E875
151
Houghton BL, Holowatz LA, Minson CT.
Influence of progestin bioactivity on cutaneous vascular responses to passive heating.
Med Sci Sports Exerc.
2005;
37
45-51
, discussion 2
152
Landau RL, Bergenstal DM, Lugibihl K, Kascht ME.
The metabolic effects of progesterone in man.
J Clin Endocrinol Metab.
1955;
15
1194-1215
153
Kagawa CM, Cella JA, Van Arman CG.
Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt.
Science.
1957;
126
1015-1016
154
Edgren RA, Elton RL.
Estrogen antagonisms: effects of several steroidal spironolactones on estrogen-induced uterine growth in mice.
Proc Soc Exp Biol Med.
1960;
104
664-665
155
Neumann F.
Intersexuality of male foetuses and inhibition of androgenic function in adult animals with a testosterone blocker.
Ger Med Month.
1967;
12
182-188
156
Cumming DC, Yang JC, Rebar RW, Yen SS.
Treatment of hirsutism with spironolactone.
JAMA.
1982;
247
1295-1298
157
Drill VA.
Endocrine properties and long-term safety of oral contraceptives.
Metabolism.
1965;
14
((Suppl))
295-310
158
Forman B, Samuels H.
Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model.
Mol Endocrinol.
1990;
4
1293-1301
159
Chang CS, Kokontis J, Liao ST.
Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors.
Proc Natl Acad Sci USA.
1988;
85
7211-7215
160
de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ.
Receptor profiling and endocrine interactions of tibolone.
Steroids.
2003;
68
21-30
161
Liu JH.
Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.
Am J Med.
2005;
118
88-92
162
Mauvais-Jarvis P, Kuttenn F, Baudot N.
Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone.
J Clin Endocrinol Metab.
1974;
38
142-147
163
Juchem M, Pollow K, Elger W, Hoffmann G, Mobus V.
Receptor binding of norgestimate - a new orally active synthetic progestational compound.
Contraception.
1993;
47
283-294
164
Wiegratz I, Kuhl H.
Progestogen therapies: differences in clinical effects?.
Trends Endocrinol Metab.
2004;
15
277-285
165
Sitruk-Ware R.
Pharmacological profile of progestins.
Maturitas.
2004;
47
277-283
166
Thomas CP, Liu KZ, Vats HS.
Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate (alpha)-ENaC and sgk1 expression in renal collecting duct epithelia.
Am J Physiol Renal Physiol.
2006;
290
F306-F312
167
Stachenfeld NS, Silva C, Keefe DL, Kokoszka CA, Nadel ER.
Effects of oral contraceptives on body fluid regulation.
J Appl Physiol.
1999;
87
1016-1025
168
Suzuki T, Nakamura Y, Moriya T, Sasano H.
Effects of steroid hormones on vascular functions.
Microsc Res Tech.
2003;
60
76-84
169
Perusquia M, Villalon CM, Navarrete E, Garcia GA, Perez-Palacios G, Lemus AE.
Vasodilating effect of norethisterone and its 5 alpha metabolites: a novel nongenomic action.
Eur J Pharmacol.
2003;
475
161-169
170
Dumont M, Luu-The V, Dupont E, Pelletier G, Labrie F.
Characterization, expression, and immunohistochemical localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in human skin.
J Invest Dermatol.
1992;
99
415-421
171
Pelletier G, Ren L.
Localization of sex steroid receptors in human skin.
Histol Histopathol.
2004;
19
629-636
172
Thody AJ, Shuster S.
Effect of progesterone on the sebaceous glands.
Postgrad Med J.
1978;
54
((Suppl 2))
88-90
173
Girard J, Barbier A, Lafille C.
Inhibition of testosterone metabolism and lipogenesis in animal sebaceous glands by progesterone.
Arch Dermatol Res.
1980;
269
281-290
174
Kanda N, Watanabe S.
Regulatory roles of sex hormones in cutaneous biology and immunology.
J Dermatol Sci.
2005;
38
1-7
175
Rosenfield RL.
Clinical practice.
Hirsutism. N Engl J Med.
2005;
353
2578-2588
176
Arowojolu AO, Gallo MF, Grimes DA, Garner SE.
Combined oral contraceptive pills for treatment of acne.
Cochrane Database Syst Rev.
2004;
CD004425
177
Thorneycroft H, Gollnick H, Schellschmidt I.
Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Cutis.
2004;
74
123-130
178
Cormia FE.
Alopecia from oral contraceptives.
JAMA.
1967;
201
635-637
179
Ross EK, Shapiro J.
Management of hair loss.
Dermatol Clin.
2005;
23
227-243
180
Freedman RR.
Hot flashes: behavioral treatments, mechanisms, and relation to sleep.
Am J Med.
2005;
118
124-130
Correspondence
C. C. Zouboulis
Departments of Dermatology and Immunology
Dessau Medical Center
Auenweg 38
06847 Dessau
Germany
Telefon: +49/340/501 40 00
Fax: +49/340/501 40 25
eMail: christos.zouboulis@klinikum-dessau.de